Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SAGE

Sage Therapeutics Inc

Apr 26 • 04:00PM ET

13.69

Dollar change +0.11
Percentage change 0.81	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF VBK IWO IBB LABU VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-8.40	Insider Own	18.39%	Shs Outstand	60.04M	Perf Week	2.70%
Market Cap	823.86M	Forward P/E	-	EPS next Y	-5.02	Insider Trans	0.00%	Shs Float	49.11M	Perf Month	-28.10%
Income	-503.14M	PEG	-	EPS next Q	-1.67	Inst Own	95.05%	Short Float	18.96%	Perf Quarter	-48.07%
Sales	91.06M	P/S	9.05	EPS this Y	28.06%	Inst Trans	0.73%	Short Ratio	9.00	Perf Half Y	-25.19%
Book/sh	11.73	P/B	1.17	EPS next Y	22.95%	ROA	-50.61%	Short Interest	9.31M	Perf Year	-70.88%
Cash/sh	11.94	P/C	1.15	EPS next 5Y	16.80%	ROE	-54.72%	52W Range	10.92 - 59.99	Perf YTD	-36.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.28%	ROI	-71.29%	52W High	-77.18%	Beta	0.91
Dividend TTM	-	Quick Ratio	12.22	Sales past 5Y	3395.58%	Gross Margin	96.12%	52W Low	25.37%	ATR (14)	1.05
Dividend Ex-Date	-	Current Ratio	12.22	EPS Y/Y TTM	10.43%	Oper. Margin	-557.93%	RSI (14)	32.92	Volatility	6.41% 6.18%
Employees	487	Debt/Eq	0.00	Sales Y/Y TTM	868.87%	Profit Margin	-552.52%	Recom	2.67	Target Price	22.29
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	26.68%	Payout	-	Rel Volume	1.44	Prev Close	13.58
Sales Surprise	50.21%	EPS Surprise	-9.16%	Sales Q/Q	139.89%	Earnings	Apr 25 BMO	Avg Volume	1.03M	Price	13.69
SMA20	-11.37%	SMA50	-27.69%	SMA200	-38.91%	Trades		Volume	1,485,851	Change	0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-24	Downgrade	BofA Securities	Neutral → Underperform	$24 → $14
Dec-12-23	Initiated	Deutsche Bank	Hold	$21
Aug-08-23	Downgrade	Needham	Buy → Hold
Aug-08-23	Downgrade	Goldman	Buy → Neutral	$22
Aug-08-23	Downgrade	Canaccord Genuity	Buy → Hold	$64 → $21
Aug-07-23	Downgrade	Wedbush	Outperform → Neutral	$51 → $22
Aug-07-23	Downgrade	Stifel	Buy → Hold	$60 → $22
Aug-07-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$71 → $25
Aug-07-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-07-23	Downgrade	BofA Securities	Buy → Neutral	$66 → $25
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Mar-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$40 → $60
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Nov-01-22	Initiated	Loop Capital	Hold	$41
Mar-31-22	Initiated	Berenberg	Hold	$37
Nov-02-21	Upgrade	Guggenheim	Neutral → Buy	$55
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight	$78 → $66
Oct-07-21	Downgrade	Jefferies	Buy → Hold	$100 → $50
Sep-23-21	Initiated	Needham	Buy	$84
Jun-16-21	Downgrade	Citigroup	Buy → Neutral	$101 → $68

Show Previous Ratings

Apr-26-24 11:27AM	Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates (Zacks)
Apr-25-24 02:33PM	Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained (MT Newswires)
10:54AM	SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:04AM	Sage Therapeutics Inc (SAGE) Q1 2024 Earnings: Mixed Results Amidst Pipeline Progress (GuruFocus.com)
07:35AM	Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Loading…
06:30AM	Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
Apr-18-24 11:37AM	Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal (Zacks)
10:01AM	Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-17-24 04:10PM	Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark (Investor's Business Daily) -19.58%
02:41PM	Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data (Benzinga)
08:46AM	Sage Therapeutics Hammered After Parkinson's Drug Misses The Mark (Investor's Business Daily)
07:44AM	Sages cognition drug fails in Parkinsons study (BioPharma Dive)
06:39AM	Sage Therapeutics' Parkinson's drug fails in mid-stage study (Reuters)
06:30AM	Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease (Business Wire)
Apr-11-24 07:29PM	12 Best All-Time Low Stocks To Invest In (Insider Monkey)
06:30AM	Loading…
06:30AM	Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 (Business Wire)
Apr-10-24 06:09PM	12 Best Depressed Stocks To Buy in 2024 (Insider Monkey)
07:47AM	New postpartum depression drugs are here. Diagnosis, treatment hurdles still stand in the way. (BioPharma Dive)
Mar-18-24 10:16AM	25 Most Stressed Cities in the United States (Insider Monkey)
Mar-15-24 11:30AM	Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report? (Zacks)
Feb-28-24 06:30AM	Sage Therapeutics to Present at Upcoming March Investor Conferences (Business Wire)
Feb-15-24 01:36PM	Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates (Zacks)
10:50AM	Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-14-24 07:15AM	Sage Therapeutics Inc (SAGE) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +11.86%
06:42AM	Sage offers details on launch of new postpartum depression pill (BioPharma Dive)
06:30AM	Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
Feb-07-24 10:00AM	Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jan-31-24 06:30AM	Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 (Business Wire)
Jan-08-24 06:32AM	Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +16.91%
06:30AM	Sage Therapeutics Announces Changes to Board of Directors (Business Wire)
06:30AM	Loading…
Jan-02-24 06:30AM	Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 (Business Wire)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -6.03%
Dec-14-23 06:30AM	ZURZUVAE (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. (Business Wire)
Dec-07-23 11:31AM	Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report? (Zacks)
Nov-13-23 11:13AM	Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 01:11PM	Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5% (Zacks) -5.76%
07:59AM	Biogens Earnings Top Estimates. Wall Street Still Has Questions About Growth. (Barrons.com)
06:30AM	Sage Therapeutics to Present at Upcoming November Investor Conferences (Business Wire)
Nov-07-23 06:02PM	Why Sage Therapeutics Stock Sank Today (Motley Fool)
05:41PM	Biogen Reports Earnings Wednesday. Heres What to Expect. (Barrons.com)
12:40PM	UPDATE 1-Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 (Reuters)
08:44AM	Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 (Reuters)
07:40AM	Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:21AM	Sage Therapeutics Inc (SAGE) Announces Q3 2023 Financial Results and Highlights Pipeline Progress (GuruFocus.com)
06:30AM	Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
06:30AM	Biogen, Sage set price of postpartum depression pill at $15,900 (BioPharma Dive)
Nov-02-23 10:00AM	VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-31-23 10:01AM	Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-24-23 06:42AM	Aristotle Atlantic's Large Cap Growth Strategy Sold Sage Therapeutics (SAGE) on Uncertainty Surrounding the Company (Insider Monkey)
06:30AM	Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 (Business Wire)
Oct-19-23 12:16PM	Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag (Zacks) -5.07%
Oct-18-23 06:30AM	Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntingtons Disease (Business Wire)
Oct-14-23 01:14PM	5 Stocks to Buy with Exponential Growth (Insider Monkey)
Sep-15-23 03:01PM	Sage Therapeutics to lose 95 employees in Cambridge in mass layoff (American City Business Journals)
Sep-13-23 04:43PM	Sage Therapeutics reveals number of layoffs in Raleigh (American City Business Journals)
Sep-06-23 02:27PM	3 Healthcare Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
06:30AM	Sage Therapeutics to Present at Upcoming September Investor Conferences (Business Wire)
Sep-01-23 03:51PM	FDA Documents Suggest Sage's Battle In Depression Drugs Will Be Trickier Than Expected (Investor's Business Daily)
01:27PM	Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why (Zacks)
Aug-31-23 11:10AM	Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment (Investor's Business Daily)
10:10AM	Sage cuts nearly half its staff in wake of partial FDA rejection (American City Business Journals)
09:36AM	Midday movers: Salesforce, Dollar General, Crowdstrike and more (Investing.com)
07:00AM	UPDATE 1-Sage Therapeutics to cut about 188 jobs after depression drug setback (Reuters)
06:44AM	Sage Therapeutics to cut about 188 jobs after depression drug setback (Reuters)
06:40AM	Sage Therapeutics to cut 40% of jobs after depression drug setback (Reuters)
06:30AM	Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE Commercial Launch and Pipeline Advancement (Business Wire)
Aug-24-23 10:23AM	3 Very Oversold Pharma Stocks to Buy Right Now (InvestorPlace)
05:10AM	Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month? (Motley Fool)
Aug-11-23 12:05PM	15 Most Important Medical Discoveries in History (Insider Monkey) +12.45%
11:23AM	Why Shares of Sage Therapeutics Slumped This Week (Motley Fool)
10:34AM	Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News (Zacks)
08:50AM	2 Beaten-Down Stocks That Still Aren't Worth Buying (Motley Fool)
Aug-08-23 09:42AM	Company News for Aug 8, 2023 (Zacks) +13.01%
09:00AM	Is Sage Therapeutics a Contrarian Buy? (Motley Fool)
06:02AM	Analysts Just Made A Major Revision To Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Forecasts (Simply Wall St.)
Aug-07-23 04:06PM	Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug (Investor's Business Daily) -53.60%
03:50PM	Sage Therapeutics Shares Plummet Following FDA Decision on Depression Drug (Investopedia)
11:58AM	Sage Therapeutics Shares Plunge After FDA Rejection (TheStreet.com)
11:44AM	Why Sage Therapeutics Stock Is Crashing Today (Motley Fool)
10:32AM	Sage shares cut in half after postpartum drug approval. Here's what happened. (American City Business Journals)
10:32AM	Sage market cap cut in half as markets open after partial drug approval (American City Business Journals)
10:14AM	FDA approves first postpartum depression pill from Biogen, Sage (Yahoo Finance Video)
10:04AM	Split FDA Call on Depression Drug Upsets Strategies for Biogen, Sage (Barrons.com)
09:57AM	American downgraded, United upgraded: Wall Street's top analyst calls (The Fly)
09:57AM	American Airlines downgraded, United upgraded: Wall Street's top analys (The Fly)
08:09AM	Sage Stock Tumbles After FDA Decision on Depression Drug (Barrons.com)
08:06AM	Sage Stock Tumbles as Depression Pill Approval Omits Major Disorder (Bloomberg)
07:40AM	Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
Aug-04-23 10:45PM	Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023 (Business Wire)
10:42PM	FDA Approves ZURZUVAE (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder (Business Wire)
08:44PM	Postpartum depression drug developed by Sage, Biogen approved by FDA (American City Business Journals)
08:13PM	UPDATE 2-US FDA approves Biogen-Sage Therapeutics pill for postpartum depression (Reuters)
07:24PM	First Pill for Postpartum Depression Is Approved by FDA (The Wall Street Journal)
07:13PM	The first pill to treat postpartum depression has been approved by US health officials (AP Finance)
07:11PM	US FDA approves Biogen-Sage Therapeutics pill for postpartum depression (Reuters)
Jul-29-23 11:39AM	10 Oversold Biotech Stocks to Buy (Insider Monkey)
Jul-26-23 03:46PM	Why Sage Therapeutics Stock Is Tumbling Today (Motley Fool) -13.47%
11:01AM	Biogens CEO Didnt Mention an Impending FDA Decision. Investors Got Spooked. (Barrons.com)
Jun-16-23 10:33AM	Sage Therapeutics (NASDAQ:SAGE) shareholders have earned a 79% return over the last year (Simply Wall St.)

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
IGUCHI KIMI	CFO & Treasurer	Jan 02 '24	Option Exercise	1.36	1,642	2,233	70,429	Jan 04 04:07 PM
Barrett Elizabeth	Director	Aug 09 '23	Buy	18.64	2,000	37,279	3,000	Aug 11 08:51 AM
Barrett Elizabeth	Director	May 09 '23	Buy	50.50	1,000	50,500	1,000	May 11 08:58 AM

Open in Screener

STTK

Shattuck Labs Inc

Apr 26 • 04:00PM ET

10.59

Dollar change +0.81
Percentage change 8.28	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

STTK Shattuck Labs Inc daily Stock Chart

Held by: VTI VXF IWC AVSC DFAC TXSS TXS DCOR

Index	-	P/E	-	EPS (ttm)	-2.05	Insider Own	14.17%	Shs Outstand	47.26M	Perf Week	10.54%
Market Cap	503.55M	Forward P/E	-	EPS next Y	-1.77	Insider Trans	-0.60%	Shs Float	40.81M	Perf Month	17.93%
Income	-87.30M	PEG	-	EPS next Q	-0.45	Inst Own	58.84%	Short Float	4.40%	Perf Quarter	6.65%
Sales	1.66M	P/S	303.35	EPS this Y	15.79%	Inst Trans	-3.74%	Short Ratio	5.51	Perf Half Y	557.76%
Book/sh	3.06	P/B	3.46	EPS next Y	-2.36%	ROA	-47.85%	Short Interest	1.80M	Perf Year	265.17%
Cash/sh	2.75	P/C	3.86	EPS next 5Y	-	ROE	-54.41%	52W Range	1.33 - 11.11	Perf YTD	48.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-63.20%	ROI	-58.94%	52W High	-4.68%	Beta	2.04
Dividend TTM	-	Quick Ratio	12.51	Sales past 5Y	40.60%	Gross Margin	-154.50%	52W Low	696.18%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	12.51	EPS Y/Y TTM	14.76%	Oper. Margin	-5549.61%	RSI (14)	62.53	Volatility	6.62% 6.73%
Employees	75	Debt/Eq	0.03	Sales Y/Y TTM	154.14%	Profit Margin	-5268.44%	Recom	1.00	Target Price	15.75
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	31.40%	Payout	-	Rel Volume	1.17	Prev Close	9.78
Sales Surprise	112.06%	EPS Surprise	27.79%	Sales Q/Q	83.08%	Earnings	Feb 29 AMC	Avg Volume	325.96K	Price	10.59
SMA20	13.46%	SMA50	14.92%	SMA200	104.66%	Trades		Volume	381,456	Change	8.28%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-22	Initiated	BTIG Research	Buy	$12
Jun-01-22	Initiated	Citigroup	Buy	$13
May-02-22	Initiated	H.C. Wainwright	Buy	$28
Apr-14-21	Initiated	Berenberg	Buy	$47
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Needham	Buy	$34
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Citigroup	Buy	$36

Apr-09-24 04:05PM	Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire)
Apr-01-24 07:00AM	Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Feb-29-24 04:05PM	Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-26-24 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
05:06AM	Loading…
Feb-14-24 05:06AM	Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins (PR Newswire) +6.03%
Feb-13-24 06:00AM	Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases (GlobeNewswire) -5.37%
Jan-08-24 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024 (GlobeNewswire) +14.94%
Jan-04-24 04:05PM	Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 08:00AM	Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire)
Dec-13-23 10:45AM	Why Is Shattuck Labs (STTK) Stock Up 93% Today? (InvestorPlace) +130.33%
06:00AM	Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Dec-05-23 04:15PM	Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023 (GlobeNewswire)
Nov-14-23 09:00AM	Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +10.05%
Nov-13-23 08:52AM	Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2023 Earnings Call Transcript (Insider Monkey)
11:54PM	Loading…
Nov-09-23 11:54PM	Q3 2023 Shattuck Labs Inc Earnings Call (Thomson Reuters StreetEvents) -23.21%
08:29AM	Shattuck Labs Inc (STTK) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
06:00AM	Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-06-23 09:28AM	Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023 (GlobeNewswire) +14.05%
Nov-02-23 09:01AM	Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +7.69%
Aug-10-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.64%
04:00PM	Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-23 10:14AM	Companies Like Shattuck Labs (NASDAQ:STTK) Could Be Quite Risky (Simply Wall St.) -7.07%
May-25-23 05:15PM	Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) -5.46%
May-09-23 05:15PM	Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.56%
04:00PM	Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-03-23 07:00AM	Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-23 11:50AM	Great week for Shattuck Labs, Inc. (NASDAQ:STTK) institutional investors after losing 37% over the previous year (Simply Wall St.)
Mar-16-23 08:31AM	Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +8.93%
07:00AM	Loading…
Mar-01-23 07:00AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire)
Feb-27-23 10:46PM	Shattuck Labs, Inc. (NASDAQ:STTK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-23-23 04:30PM	Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-16-23 07:00AM	Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023 (GlobeNewswire)
Feb-09-23 06:01AM	Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-27-23 08:34AM	We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-09-23 07:00AM	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023 (GlobeNewswire)
Dec-13-22 06:51AM	Multiple insiders bought Shattuck Labs, Inc. (NASDAQ:STTK) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Dec-01-22 09:55AM	Shattuck Labs, Inc. (STTK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-11-22 05:51AM	Shattuck Labs Third Quarter 2022 Earnings: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021) (Simply Wall St.)
Nov-08-22 04:30PM	Shattuck Labs Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -6.75%
Nov-07-22 08:00AM	Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-22 11:55AM	Investors in Shattuck Labs (NASDAQ:STTK) have unfortunately lost 86% over the last year (Simply Wall St.)
Nov-03-22 08:30AM	Shattuck Labs Announces Participation in Upcoming November Conferences (GlobeNewswire)
Nov-01-22 04:30PM	Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire)
Oct-12-22 10:04AM	Owning 38% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK), (Simply Wall St.) +10.51%
Oct-05-22 04:30PM	Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12 (GlobeNewswire) +10.00%
Sep-01-22 04:15PM	Shattuck Labs Announces Participation in Upcoming September Conferences (GlobeNewswire)
Aug-20-22 08:41AM	We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth Carefully (Simply Wall St.)
Aug-11-22 07:00AM	Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-06-22 07:20AM	Quite a few insiders invested in Shattuck Labs, Inc. (NASDAQ:STTK) last year which is positive news for shareholders (Simply Wall St.) +20.93%
May-28-22 08:05AM	Shareholders in Shattuck Labs (NASDAQ:STTK) are in the red if they invested a year ago (Simply Wall St.)
May-13-22 08:50AM	Should You Buy Shattuck Labs (STTK) Ahead of Earnings? (Zacks)
May-12-22 07:00AM	Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +8.28%
May-06-22 09:00AM	Why Earnings Season Could Be Great for Shattuck Labs (STTK) (Zacks) -7.28%
May-05-22 09:14AM	What Type Of Shareholders Own The Most Number of Shattuck Labs, Inc. (NASDAQ:STTK) Shares? (Simply Wall St.) -7.03%
Apr-08-22 04:55PM	Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-05-22 05:00PM	Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-22 12:00PM	Shattuck Labs, Inc. (NASDAQ:STTK) Analysts Just Trimmed Their Revenue Forecasts By 45% (Simply Wall St.) -7.81%
Mar-15-22 07:00AM	Shattuck Labs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-09-22 08:21AM	Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-02-22 08:39AM	Shattuck Labs Announces Participation in Upcoming March Conferences (GlobeNewswire) -6.99%
Feb-09-22 05:00PM	Shattuck Labs Announces Participation in Upcoming 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-02-22 01:38PM	Investment Management Of Virginia Llc Buys PowerShares QQQ Trust Ser 1, Dow Inc, Apple Inc, ... (GuruFocus.com) -9.30%
Jan-27-22 09:21AM	A Shattuck Labs, Inc. (NASDAQ:STTK) insider increased their holdings by 3.6% last year (Simply Wall St.) -5.75%
Jan-05-22 08:30AM	Shattuck Labs Announces Participation in Upcoming January Investor Conferences (GlobeNewswire) -6.49%
Dec-13-21 01:57PM	Shareholders in Shattuck Labs (NASDAQ:STTK) are in the red if they invested a year ago (Simply Wall St.) -5.02%
Dec-03-21 07:59PM	ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (Newsfile)
Dec-02-21 03:40PM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Shattuck Labs, Inc. with Losses of $100,000 to Contact the Firm (ACCESSWIRE) +7.02%
07:17AM	Shattuck Labs to Present at TIGIT Therapies Digital Summit 2021 (GlobeNewswire)
Dec-01-21 10:45PM	STTK BREAKING NEWS: ROSEN, A LEADING NATIONAL FIRM, Encourages Shattuck Labs, Inc. Investors with Losses to Inquire About Class Action Investigation - STTK (PR Newswire)
Nov-29-21 10:30AM	INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Shattuck Labs, Inc. with Losses of $100,000 to Contact the Firm (ACCESSWIRE) -8.50%
Nov-28-21 07:58PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Shattuck Labs, Inc. - STTK (Newsfile)
Nov-26-21 12:39PM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (Business Wire) -7.19%
Nov-25-21 11:23PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Shattuck Labs, Inc. - STTK (PR Newswire)
05:00PM	ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Shattuck Labs, Inc. Investors with Losses to Inquire About Class Action Investigation STTK (GlobeNewswire)
Nov-23-21 05:44PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm (Business Wire)
Nov-22-21 01:00PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Shattuck Labs, Inc. (STTK) Investigation (ACCESSWIRE)
09:47AM	EQUITY ALERT: Rosen Law Firm Encourages Shattuck Labs, Inc. Investors with Losses to Inquire About Class Action Investigation STTK (Business Wire)
Nov-21-21 11:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Shattuck Labs, Inc. - STTK (ACCESSWIRE)
Nov-18-21 04:01PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Shattuck Labs, Inc. - STTK (GlobeNewswire) -7.78%
Nov-15-21 11:32PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Shattuck Labs, Inc. - STTK (Newsfile)
Nov-11-21 05:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Shattuck Labs, Inc. - STTK (ACCESSWIRE)
Nov-10-21 12:30PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Shattuck Labs, Inc. (STTK) Investigation (ACCESSWIRE) -7.80%
Nov-09-21 01:19PM	Takeda, Shattuck Labs Terminate Immuno-Oncology Pact (Benzinga) -28.62%
08:00AM	Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
08:00AM	Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252 (GlobeNewswire)
Nov-04-21 07:00AM	Shattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-03-21 05:19PM	Shattuck Labs Announces Participation in Upcoming November Investor Conferences (GlobeNewswire)
Oct-28-21 04:30PM	Shattuck Labs Announces Changes to its Board of Directors (GlobeNewswire)
Oct-12-21 11:11AM	What Type Of Shareholders Own The Most Number of Shattuck Labs, Inc. (NASDAQ:STTK) Shares? (Simply Wall St.) -5.22%
Oct-01-21 09:56AM	Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-01-21 04:30PM	Shattuck Labs Announces Participation in Upcoming September Conferences (GlobeNewswire)
Aug-11-21 04:30PM	Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252 (GlobeNewswire)
Aug-06-21 10:40AM	Shattuck Labs Announces Participation in the BTIG Biotechnology Conference (GlobeNewswire)
Aug-04-21 08:00AM	Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021 (GlobeNewswire)
Jul-13-21 08:00AM	We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely (Simply Wall St.)
Jun-01-21 10:44AM	Shattuck Labs Appoints Abhinav A. Shukla as Chief Technical Officer (GlobeNewswire)
May-10-21 07:00AM	Shattuck Labs Reports First Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire) -7.52%
Apr-30-21 05:33PM	Shattuck Labs Announces Participation in Upcoming May Conferences (GlobeNewswire)

Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. It primarily focuses on Agonist Redirected Checkpoint (ARC) and Gamma Delta T Cell Engagers (GADLEN) platforms. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stout Stephen	See Remarks	Mar 06 '24	Option Exercise	3.54	11,109	39,380	85,791	Mar 08 05:40 PM
Stout Stephen	See Remarks	Mar 06 '24	Sale	10.53	16,004	168,522	74,437	Mar 08 05:40 PM
Neill Andrew R	Chief Financial Officer	Jan 10 '24	Sale	10.00	25,000	250,000	173,446	Jan 16 04:35 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SAGE

Sage Therapeutics Inc

STTK

Shattuck Labs Inc

Upgrade your FINVIZ experience